Market Exclusive

ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) Files An 8-K Submission of Matters to a Vote of Security Holders

ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders.

Alexion Pharmaceuticals, Inc. held its Annual Meeting of
Shareholders on May 10, 2017 in New Haven, Connecticut. The results
of the matters voted on by the shareholders are set forth below.
1. The election of directors:
Votes For
Votes Against
Abstentions
Broker
Non-Votes
Felix Baker
196,267,971
619,661
272,464
7,263,638
David R. Brennan
195,482,894
1,405,436
271,766
7,263,638
M. Michele Burns
172,282,654
24,605,678
271,764
7,263,638
Christopher J. Coughlin
196,037,779
849,761
272,556
7,263,638
Ludwig Hantson
196,100,754
362,478
696,864
7,263,638
John T. Mollen
194,479,863
2,403,223
227,010
7,263,638
R. Douglas Norby
193,798,065
3,077,770
284,261
7,263.638
Alvin S. Parven
193,387,520
3,488,246
284,330
7,263,638
Andreas Rummelt
196,281,132
606,646
272,318
7,263,638
Ann M. Veneman
195,965,172
923,105
271,819
7,263,638
2.
Approval of the Alexion Pharmaceuticals, Inc. 2017 Incentive
Plan:
Votes For
Votes Against
Abstentions
Broker Non-Votes
189,851,865
7,140,844
167,387
7,236,638
3.
Ratification of the appointment of PricewaterhouseCoopers LLP
as Alexion’s independent registered public accounting firm:
Votes For
Votes Against
Abstentions
202,869,029
1,266,458
288,247
4.
The non-binding advisory vote to approve the compensation
paid to Alexions named executive officers as described in
Alexions 2017 proxy statement:
Votes For
Votes Against
Abstentions
Broker Non-Votes
190,818,160
5,556,203
785,733
7,263,638
5.
The non-binding advisory vote to recommend the frequency of
the non-binding advisory vote to approve the compensation
paid to Alexions named executive officers. Based on the
Boards recommendation and the results of the vote, the Board
has determined to hold the advisory vote every year.
1 year
2 years
3 years
Abstentions
178,218,411
483,598
18,161,322
296,765
6.
Shareholder proposal to implement confidential shareholder
voting on executive pay matters:
Votes For
Votes Against
Abstentions
Broker Non-Votes
9,844,366
185,756,642
1,559,088
7,263,638
Item 8.01 Other Events.>
On May 10, 2017, the Board of Directors of Alexion Pharmaceuticals,
Inc. appointed David Brennan Chairman of the Board of Directors. As
previously announced, Leonard Bell retired from the Board,
effective as of the 2017 Annual Meeting of Shareholders held on May
10, 2017.

About ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders. ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) Recent Trading Information
ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) closed its last trading session up +1.04 at 120.08 with 3,007,170 shares trading hands.

Exit mobile version